Alpha Tau Medical successfully treated the first patient in Europe using its Alpha DaRT alpha-radiation therapy combined with capecitabine for inoperable locally advanced pancreatic cancer (LAPC) in the ACAPELLA clinical trial at CHU Grenoble Alpes, France. This trial targets patients who have completed first-line mFOLFIRINOX chemotherapy but have no standard consolidation therapy, addressing a critical unmet need for about 42,000 European patients annually. The treatment involves direct intratumoral delivery of alpha-emitting radium-224 sources, aiming to destroy tumors while sparing healthy tissue. The ACAPELLA trial will evaluate safety and efficacy, with results expected to contribute to global efforts alongside a parallel US trial to improve outcomes for this lethal cancer type.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
